Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

Single immune checkpoint blockade in advanced neuroendocrine neoplasms (NENs) shows limited efficacy; dual checkpoint blockade may improve treatment activity. Dune (NCT03095274) is a non-randomized controlled multicohort phase II clinical trial evaluating durvalumab plus tremelimumab activity and sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Capdevila, J., Hernando, J., Teule, A., Lopez, C., Garcia-Carbonero, R., Benavent, M., Custodio, A., Garcia-Alvarez, A., Cubillo, A., Alonso, V., Carmona-Bayonas, A., Alonso-Gordoa, T., Crespo, G., Jimenez-Fonseca, P., Blanco, M., Viudez, A., La Casta, A., Sevilla, I., Segura, A., Llanos, M., Landolfi, S., Nuciforo, P., Manzano, J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204675/
https://www.ncbi.nlm.nih.gov/pubmed/37221181
http://dx.doi.org/10.1038/s41467-023-38611-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204675/
https://www.ncbi.nlm.nih.gov/pubmed/37221181
http://dx.doi.org/10.1038/s41467-023-38611-5

Ejemplares similares